Table 1.

Baseline characteristics, immunosuppression, and graft outcome in IVIg-treated patients and control subjectsa

ParameterIVIg-Treated Patients(n = 27)Control Group(n = 27)P
Recipient characteristics
    age (yr; mean ± SD)45 ± 10.548 ± 9.4NS
    weight (kg; mean ± SD)58.7 ± 10.668.9 ± 14.6<0.010
    female (n [%])13 (48.1)5 (19.5)<0.020
Transplant characteristics
    donor age (yr; mean ± SD)46.4 ± 14.650.2 ± 10.6NS
    cold ischemia time (h; mean ± SD)25.2 ± 8.219.7 ± 6.0<0.005
    delayed graft function (n [%])18 (66.7)15 (55.6)NS
    cyclosporine at 3 mo (n [%])4 (14.8)7 (25.9)NS
    cyclosporine C2 at 3 mo (ng/ml; mean ± SD)1143 ± 328869 ± 423NS
    cyclosporine at 1 yr (n [%])3 (11.1)6 (22.2)NS
    cyclosporine C2 at 1 yr (ng/ml; mean ± SD)1298 ± 509743 ± 1690.050
    tacrolimus at 3 mo (n [%])23 (85.2)20 (74.1)NS
    tacrolimus C0 at 3 mo (ng/ml; mean ± SD)11.1 ± 3.010.4 ± 3.2NS
    tacrolimus at 1 yr (n [%])24 (88.9)21 (77.8)NS
    tacrolimus C0 at 1 yr (ng/ml; mean ± SD)7.7 ± 1.99.2 ± 2.4<0.050
Graft outcome
    serum creatinine at 3 mo (μmol/L; mean ± SD)133 ± 44132 ± 39NS
    CrCl at 3 mo (ml/min per 1.73 m2)a50 ± 1360 ± 18<0.050
    proteinuria at 3 mo (g/d; mean ± SD)0.28 ± 0.400.18 ± 0.20NS
    serum creatinine at 1 yr (μmol/L; mean ± SD)143 ± 65131 ± 36NS
    CrCl at 1 yr (ml/min per 1.73 m2)a50 ± 2159 ± 21NS
    proteinuria at 1 yr (g/d; mean ± SD)0.31 ± 0.700.18 ± 0.32NS
    acute rejection at 3 mo (n [%])7 (25.9)2 (7.4)NS
    acute rejection 3 mo to 1 yr (n [%])2 (7.4)2 (7.4)NS
    acute rejection at 1 yr (n [%])8 (29.6)4 (14.8)NS
  • a CrCl, creatinine clearance calculated by the Cockcroft-Gault formula (18); IVIg, intravenous immunoglobulin.